Diabetic neuropathy
Therapeutic area
Neurology
Rare disease
No
- Definition
- A chronic, pathological complication associated with diabetes mellitus, where nerve damages are incurred due to diabetic microvascular injury involving small blood vessels that supply these nerves, resulting in peripheral and/or autonomic nerve dysfunction.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diabetic neuropathy
- Therapeutic area
- Neurology
- diabetic neuropathy
- Diabetic Neuropathy, Distal Symmetric Polyneuropathy (Manifestation)
- Diabetic Neuropathy, Painful
- All therapeutic areas
- Neurology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0006626
- Parent condition
- MONDO:0005244
Related records
Broader conditions (7)
- Disease
- Disease by body system or component
- Human disease
- Nervous system disorder
- Neuromuscular disease
- Peripheral nervous system disorder
- Peripheral neuropathy
Narrower conditions (2)
- Diabetic autonomic neuropathy
- Diabetic polyneuropathy
Trials (750)
- 0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
- 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study
- 24-hour Blood Pressure Dynamics and Autonomic Adrenergic Regulation in Type 2 Diabetics
- 3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy
- A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy
- A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
- A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
- A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
- A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy
- A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
- A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).
- A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
- A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract
- A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
- A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
- A Long-term Study for the Treatment of Painful Diabetic Neuropathy
- A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
Approved drugs (2)
- Duloxetine hydrochloride
- Epalrestat
Drugs in development (106)
- Acetaminophen Phase 3
- Actovegin Phase 3
- Amitriptyline Phase 2
- Ascorbic acid Phase 1
- Astaxanthin Phase 2
- AZD2066 Phase 2
- Benfotiamine Phase 3
- Bevacizumab Phase 1
- Bicifadine Phase 2
- Bicifadine hydrochloride Phase 2
- BIIB-095 Phase 1
- Cannabidiol Phase 2
- Cannabinol Phase 1
- Capsaicin Phase 3
- Carisbamate Phase 2
- CBX-129801 Phase 2
- Cebranopadol Phase 3
- Centella asiatica extract Phase 2
- Clofutriben Phase 2
- Clonidine Phase 2
Other linked drugs (11)
- Botulinum toxin type A
- Cholecalciferol
- Dextrose
- Diphenhydramine
- Diphenhydramine citrate
- Human immunoglobulin G
- Letibotulinumtoxina
- Liraglutide
- Onabotulinumtoxina
- Pirenzepine hydrochloride
- Zenarestat